**1. Introduction**

Pro-/sym-/synbiotics are important objects of human microecology and medical biotechnology [1–4]. Microbes and human communicate each other by the way of recognition and binding glycoconjugates (GC) of varying pattern complexity by proteins (mainly adhesions and lectins) [5–9]. Lectin systems (LS) of symbiotic/ probiotic microorganisms (LSSM) recognizing GC represent new multifunctional factors [8–12]. LSSM are relatedly useful for human protein-/peptide-containing compounds and their complexes recognizing GC. LSSM reveal features of imitators of probiotics; members of new class of bacteriocin-like destructors of biofilms of yeast-like fungal and Gram-positive pathogens; systems cofunctioning together

with enzymes of all known classes; and agents possessing antipathogenic synergism of different LS in antimicrobial combinations (between LS of *Lactobacillus* species and *Bifidobacterium* species, between genera *Lactobacillus* and *Bifidobacterium*, between LS of probiotic bacteria and lectins from medical plants, between LSSM and antibiotics) (see **Table 2**) [8, 9, 13, 14].

LS reveal significantly higher multifunctionality (antimicrobial, cytokine-like, others) and adaptive ability in surroundings in comparison to any component of LS. Applied prospects of LSSM in microbial associations of biotopes in the human body are of promised interest. LSSM and their reactive GC support balanced functioning in organism in respect to evolutionary created mucosal organ-like infrastructures of mutual interest for human and biotope microbiocenoses (MB) [12].

The purpose of the review is to evaluate our approaches in creation of probiotic metabolite compositions influencing and improving health of human biotope microbiocenoses. The data presented will be of interest for investigators in the fields of both medical microbiology and laboratory and industrial medical biotechnology.
